What Factors Propelled The Growth Of The Small Molecule API Market In The Past?
The small molecule api market has seen considerable growth due to a variety of factors.
• Over the past few years, the market size of small molecule api has seen notable growth. The market is projected to expand from $204.47 billion in 2024 to $218.35 billion in 2025, growing at a compound annual growth rate (CAGR) of 6.8%. The growth throughout the historic period has been influenced by factors such as the rise in generic drug production, higher investment in research and development, increasing demands due to an aging population, expansion in cancer treatments, and the introduction of targeted therapies.
How Will the Small Molecule API Market?
The Small Molecule API market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of the small molecule API is projected to experience robust development in the following years. It is forecasted to rise to $296.47 billion in 2029 with a compound annual growth rate (CAGR) of 7.9%.
The increase during the forecasted timeframe is due to factors such as supply chain resilience, digitalization of pharmaceutical manufacturing, rising investment in oncology, the use of green chemistry and the health needs prompted by the pandemic. Key trends expected during this period consist of biopharmaceutical synergy, customized medicine, advanced production methods, API outsourcing, and contract manufacturing.
Which Factors Are Boosting Growth In The Small Molecule API Market?
The small-molecule API market is projected to expand due to an increasing demand for small-molecule drugs. These are low-molecular-weight compounds that can interrupt biochemical reactions to diagnose, treat, or prevent diseases. Examples of such drugs frequently found in medicine cabinets include aspirin and diphenhydramine. They fall under the umbrella of small molecule API products, which aim to prevent diseases. For example, a report in December 2023 by the Office of the Assistant Secretary for Planning and Evaluation, a department of the US government, stated that in 2022, a single manufacturer produced 43% of all small-molecule drugs, accounting for 65% of the total expenditure in this market. Consequently, the rising demand for these types of drugs is fuelling the expansion of the small-molecule API market.
What Key Areas Define The Segmentation Of The Global Small Molecule API Market?
The small molecule api market covered in this report is segmented –
1) By Type: Synthetic, Biotech
2) By Manufacturer: In-House, Outsourced
3) By Application: Cardiology, Oncology, CNS And Neurology, Orthopedic, Endocrinology, Other Applications
Subsegments:
1) By Synthetic: Chemical Synthesis, Process Development, Custom Synthesis
2) By Biotech: Recombinant Proteins, Monoclonal Antibodies, Peptides
Pre-Book The Small Molecule API Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Small Molecule API Market?
The trend of strategic alliances is shaping the landscape of the small-molecule API sector. Numerous companies in the small-molecule API vertical are seeking partnerships to bolster their stance and accelerate various drug and therapy developments. To illustrate, in March 2023, there was a significant collaboration between CatSci Ltd., a UK pharmaceutical company, and AGC Pharma Chemicals, a pharmaceutical entity based in Spain for enhanced drug development. AGC's manufacturing expertise is now utilized by the non-clinical specialty of CatSci, aiding clinical phase projects. CatSci's advanced competences in therapeutic development are made available to AGC's clients, specifically focusing on scalable small molecule API production and a range of technologies. The alliance puts emphasis on smooth tech transfer, with goals to provide strategic worth, fast-track development timelines of drugs, and globally distribute transformative small molecule API-based medications.
Who Are the Key Players In The Small Molecule API Market?
Major companies operating in the small molecule api market include:
• Merck & Co. Inc.
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Cambrex Corporation
• Lonza Group AG
• Siegfried Holding AG
• AstraZeneca
• F. Hoffmann-La Roche AG
• Nanjing King-friend Biochemical Pharmaceutical Co. Ltd
• Albany Molecular Research Inc.
• BASF SE
• Gilead Sciences Inc.
• GlaxoSmithKline PLC
• Johnson Matthey PLC
• Novartis AG
What Is The Most Dominant Region In The Small Molecule API Market?
North America was the largest region in the small molecule API market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the small molecule API market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
